caspofungin acetate · Fresenius Kabi Usa · NDA 206110
Caspofungin Acetate
Earliest generic entry, as listed · earliest of 2 marketed strengths
21 Dec 2032
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 9636407.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9636407 | drug product · sets the listed date | 21 Dec 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206110 · 001 | powder, intravenous | 50MG/VIAL | 21 Dec 2032 |
| 206110 · 002 | powder, intravenous | 70MG/VIAL | 21 Dec 2032 |